Amundi Cuts Stake in Edwards Lifesciences Stock
An institutional investor reduced its Edwards Lifesciences stake, selling 90,461 shares and holding 2,579,748 shares. Rehmann Capital Advisory Group bought 130 shares and now owns 6,399 valued at about $546,000. Quadrant Capital added 0.9% and Aspen Investment Management gained 1.5%. A vice president sold shares totaling $56,966.57 and $49,536.64, leaving 40,034 shares. Citigroup lifted its price target to $110 and kept a buy rating.